Latest stories on VERU
Veru refocuses sabizabulin on post-daraxonrasib oncology
TipRanks56 · neutralproduct/pr
VERU INC. (VERU) files 8-K
SEC 8-K50 · neutralgeneral
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
Business Insider56 · neutralgeneral
Veru (VERU) Q3 2026 Earnings Call Transcript
The Motley Fool50 · neutralearnings
Veru targets Q1 2027 PLATEAU interim analysis after enrolling 239 patients
Seeking Alpha58 · neutralproduct/pr
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
VERU INC. (VERU) files 8-K
SEC 8-K50 · neutralgeneral
Veru Non-GAAP EPS of -$0.30 beats by $0.02
Seeking Alpha56 · neutralearnings
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
Business Insider50 · neutralgeneral
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
Business Insider55 · neutralgeneral
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day | VERU Stock News
StockTitan56 · neutralproduct/pr
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
Business Insider56 · neutralproduct/pr
Veru Establishes At-the-Market Equity Offering Program
TipRanks24 · bearishgeneral
VERU INC. (VERU) files 8-K
SEC 8-K50 · neutralgeneral
Wall Street sees huge upside as Novo Nordisk backs biotech company
The Street73 · bullishproduct/pr
Veru to Conduct Enobosarm Clinical Study With Novo Nordisk's Weight-Loss Pill Wegovy
Morningstar56 · neutralproduct/pr
Veru, Novo Nordisk partner on enobosarm-Wegovy trial
TipRanks63 · neutralproduct/pr